Microbiomas Foundation

microbiomas.org

Microbiomas Foundation is a basic & applied research initiative established in Colombia aiming to advance and disseminate cutting edge knowledge and innovative microbial molecular and genetic engineering applications for the greater benefit of our society and our environment, collaborating with governmental agencies and institutions and the industrial sector on microbial bioremediation, environmental biotechnology, ecogenomics and functional metagenomics by studying microbiomes composition, functions and interactions in open environments and in holobiont association.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

AKTIS ONCOLOGY ANNOUNCES ACTINIUM-225 SUPPLY AGREEMENTS WITH LEADING ISOTOPE PRODUCERS

Aktis Oncology | August 24, 2022

news image

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225. "Given the breadth and depth of our emerging pipeline, securing robust isotope s...

Read More

GENETIC CANCER PATIENTS REPORT COVID-19 CRISIS IMPACTS MEDICAL CARE

VHL Alliance | April 22, 2020

news image

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Read More

CELLECT BIOTECHNOLOGY ANNOUNCES POSITIVE DATA DEMONSTRATING ROBUST ENGRAFTMENT USING APOGRAFT WAS FEATURED IN BONE MARROW TRANSPLANTATION

PR Newswire | May 11, 2020

news image

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers...

Read More

MedTech, Industrial Impact

ATRECA AND XENCOR LAUNCH NEW PROGRAM TO DEVELOP T CELL ENGAGING BISPECIFIC ANTIBODY

Atreca, Inc. | February 07, 2023

news image

On February 6, 2023, Atreca, Inc. (Atreca), a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics, and Xencor, Inc., a clinical-stage biopharmaceutical company that develops cytokines and engineered antibodies for the treatment of autoimmune diseases and cancer, announced, as part of their existing strategic collaboration, that they have mutually selected the first progr...

Read More
news image

Cell and Gene Therapy

AKTIS ONCOLOGY ANNOUNCES ACTINIUM-225 SUPPLY AGREEMENTS WITH LEADING ISOTOPE PRODUCERS

Aktis Oncology | August 24, 2022

Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced agreements with three leading medical radioisotope manufacturers NorthStar Medical Radioisotopes LLC, Niowave, Inc, and TerraPower LLC, for preclinical, clinical, and commercial supply of Actinium-225. "Given the breadth and depth of our emerging pipeline, securing robust isotope s...

Read More
news image

GENETIC CANCER PATIENTS REPORT COVID-19 CRISIS IMPACTS MEDICAL CARE

VHL Alliance | April 22, 2020

New research shows patients with von Hippel-Lindau (VHL) disease, a genetic oncological disorder, are experiencing delay and cancellation of important appointments and even surgery due to the COVID-19 public health crisis. For many people with rare diseases, these effects may be life-changing, particularly for otherwise young and healthy patients who may face irreversible damage as a result of delayed treatment. VHL, or von Hippel-Lindau disease, is a genetic disorder characterized by tumors in ...

Read More
news image

CELLECT BIOTECHNOLOGY ANNOUNCES POSITIVE DATA DEMONSTRATING ROBUST ENGRAFTMENT USING APOGRAFT WAS FEATURED IN BONE MARROW TRANSPLANTATION

PR Newswire | May 11, 2020

Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative technology which enables the functional selection of stem cells, today announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'. The article is co-authored by researchers...

Read More
news image

MedTech, Industrial Impact

ATRECA AND XENCOR LAUNCH NEW PROGRAM TO DEVELOP T CELL ENGAGING BISPECIFIC ANTIBODY

Atreca, Inc. | February 07, 2023

On February 6, 2023, Atreca, Inc. (Atreca), a biotechnology company that develops novel therapeutics through a deep understanding of the human immune response, with a focus on innovative novel cancer immunotherapeutics, and Xencor, Inc., a clinical-stage biopharmaceutical company that develops cytokines and engineered antibodies for the treatment of autoimmune diseases and cancer, announced, as part of their existing strategic collaboration, that they have mutually selected the first progr...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us